AUS
NZ
UK
CA
USA
IND
Highlights
- The American Medical Association's approval of new CPT codes for Vivos' devices marks a major milestone. These codes, effective next year, will facilitate streamlined insurance coverage and reimbursement for the company's FDA-cleared oral medical devices designed to treat obstructive sleep apnea.
- This development is expected to expand access to Vivos’ technology across a broader demographic. The codes will allow a more diverse patient population to benefit from Vivos' airway remodeling devices, which are the only FDA-cleared option for treating moderate to severe sleep apnea.
- Vivos Therapeutics is positioned for growth with this regulatory achievement. The company's CEO sees this as part of a larger strategy, including recent approvals and new marketing efforts, which will drive revenue and help more patients access life-changing treatments.
A Prominent player of Healthcare sector, Vivos Therapeutics has announced a significant regulatory achievement that could expand access to its obstructive sleep apnea (OSA) treatment devices. The American Medical Association (AMA) has approved new Current Procedural Terminology (CPT) codes for Vivos' CARE oral medical devices, a move expected to streamline insurance coverage and reimbursement. These devices, designed to treat moderate to severe OSA in both adults and children, are the only FDA-cleared airway remodeling solutions on the market.
Starting January next year, the new CPT codes will allow patients to navigate insurance claims more easily, removing a key barrier to receiving treatment. The ability to secure coverage for these devices means a wider population will have access to Vivos' innovative approach to treating sleep apnea. According to Vivos’ leadership, this breakthrough comes at a time when the company is already making strides in expanding its presence in the healthcare market.
Vivos Therapeutics (NASDAQ:VVOS) 's CEO emphasized the importance of these new codes in making their technology accessible to a larger demographic. With obstructive sleep apnea affecting millions worldwide, the need for effective, widely available treatments has never been greater. The approval of these CPT codes will enable healthcare providers to offer Vivos' devices to more patients, allowing them to treat their sleep apnea without the financial burden often associated with out-of-pocket medical expenses.
This regulatory approval follows other strategic initiatives by the company, including a new marketing and distribution model. Together with the CPT codes, Vivos believes these efforts will enhance its market position and support long-term business objectives. The company’s continued focus on regulatory and insurance advancements highlights its commitment to providing innovative healthcare solutions for patients dealing with obstructive sleep apnea.
